

MAY. 13. 2005 3:21PM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

NO. 5207 P. 1

PTO/SB/21 (09-04)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/789,053	RECEIVED
Filing Date	February 27, 2004	CENTRAL FAX CENTER
First Named Inventor	Wolfgang HOLLA et al.	
Art Unit	1626	MAY 13 2005
Examiner Name	LEE, Susannah E.	
Attorney Docket Number	DEAV2003/0014US NP	

11

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Restriction Requirement-10 pgs.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)		Remarks
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Barbara E. Kury's	Reg. No.	34,650
Date	May 13, 2006		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 11)

Signature		Date	May 13, 2005
Typed or printed name	Bonnie Stein		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

HOLLA, et al

Examiner: LEE, Susannah E.

**RECEIVED
CENTRAL FAX CENTER**

Application No.:

10/789,053

Art Unit: 1626

MAY 13 2005

Filed:

February 27, 2004**TELEFAX CERTIFICATE**Title: **Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

May 13, 2005

Date of Transmission

Bonnie Stein
Signature *Bonnie Stein*RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This paper is filed in response to the Office Action of April 13, 2005.

In response to the Restriction Requirement imposed by the Examiner in the above-referenced Office Action, Applicant proposes to elect a Group that was not as yet defined by the Examiner in the above-referenced Office Action. Applicant proposes a Group drawn to a process of preparing a chiral, nonracemic compound of the formula (I), wherein: R2 is (C1-C8)alkyl; Ring A is phenyl; R3 is (C1-C6)alkyl, R4 and R5 are hydrogen or (C1-C6)alkyl; n is 1.

Per Examiner's request to elect a single disclosed species, Applicant hereby elects the species disclosed in example 8 which is (1R,3S)-2-[3-[2-(4-methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl-1-oxymethyl]-6-methylbenzoic acid. The Examiner also requested an exact definition of each substitution on the base molecule (Formula I) wherein a single member of each substituent group or moiety is selected. For the species elected above, the following definitions apply:

Ring A is phenyl;

R3 is (C1-C6)alkyl;

R4, R5 are H and (C1-C6)alkyl, respectively;


n is 1;

R2 is (C1-C8)alkyl, wherein alkyl is substituted by (C6-C10)-aryl, and wherein aryl in turn is substituted by COOH and (C1-C6)-alkyl.

Applicant also desires to add two new dependent claims. These new claims are directed to the synthesis of specific compounds of formula I within the Group defined above. These species are described in Examples 5 and 8.

Applicant submits that the instant Response does not require a fee. However, the Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 180-1982.

Respectfully submitted,


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0014US NP